Search results
Found 9435 matches for
Nuffield Department of Women's & Reproductive Health sits within the Medical Sciences Division of the University of Oxford. The department encompasses multi-disciplinary research across four overarching themes; Cancer, Global Health, Maternal & Fetal Health and Reproductive Medicine & Genetics
Oxford University Global Surgery Group
The Nuffield Department of Women's & Reproductive health is part of the Oxford University Global Surgery Group (OUGSG), a interdepartmental group of the Medical Sciences Division for clinicians in surgery, anaesthesia, obstetrics and gynaecology with an interest in global surgical issues.
Cardiovascular Disease
Cardiovascular diseases are the leading cause of death in the world. The work of this research group integrates large databases of electronic health records, clinical trials, meta-analyses and digital technologies to better understand the determinants and consequences of cardiovascular disease, and how to improve quality of care and health outcomes.
SMARThealth Pregnancy: Improving women’s life-long health in rural India
Every year, millions of women die from heart disease, stroke and complications of diabetes, with the greatest number of deaths occurring in low-resource settings, such as parts of rural India. Prof Jane Hirst and Dr D Praveen (the George Institute for Global Health) lead the SMARThealth Pregnancy programme, which aims to help community health workers identify women at risk during pregnancy and manage their healthcare in order to reduce improve pregnancy outcomes and prevent future health complications.
Fertility Preservation
Developing novel techniques to preserve the fertility of children and young adults.
Rhino Fertility Project
Prof Suzannah Williams and her research team have begun work to find a new way of saving the Northern White Rhino by using tissue taken from animal ovaries to produce potentially large numbers of eggs in a laboratory setting.
Nanoparticles in Cancer
Our research focuses on the use of nanoparticles in cancer for therapy, imaging or drug delivery.
Assisted Reproductive Technology (ART)
Assisted Reproductive Technology (ART) research seeks to shed light on the factors responsible for reproductive failure. We are also actively engaged in efforts to improve infertility treatments, such as in vitro fertilisation (IVF). Our work aims to simplify treatments and reduce risks, increase success rates and lower costs.
Oocytes and Ovaries
Our research focusses on understanding the intricate and complex mechanisms that regulate oocyte and follicle development in health and disease. The overarching goal is to develop new fertility treatments and fertility preservation methods for girls and women.
Mitochondria
This research examines how we modulate Mitochondrial quality control as an alternative to high profile Mitochondrial donation. This will enable families with Mitochondrial disease to have healthy children.
Pre-eclampsia
Pre-eclampsia affects 5% of pregnant women, usually during the second half of pregnancy (from around 20 weeks) or soon after their baby is delivered. It is associated with significant problems in the mother and the baby. Our research examines the molecular mechanisms of pre-eclampsia and explores if we can predict and prevent this disease.
Miscarriage
Our work focuses on the pre pregnancy risk factors that pre dispose a complicated pregnancy (such as pre term babies, pre eclampsia or miscarriage)
Pain in Women
Our work aims to optimise pain relief and quality of life for women with chronic pain by improving our understanding of the mechanisms generating pain in women and the interaction between hormones and pain.
Ovarian Cancer
Ovarian cancer is one of the most lethal gynaecological malignancies predominantly because of late presentation and chemotherapy resistance. Recent advances in single cell RNA sequencing and DNA sequencing have made it possible to obtain unprecedented insights into tumour biology. Our lab has developed sequencing strategies and analysis algorithms to accelerate the mechanistic understanding of ovarian cancer initiation, progression and chemotherapy resistance. The use of these technologies and our access to patients recruited in clinical research studies provide exciting opportunities for addressing key questions in ovarian cancer such as a) understanding the cell of origin of ovarian cancer, b) characterising the tumour initiating cells in minimal residual disease and c) understanding T cell immune responses against ovarian cancer initiation and progression.
INTERGROWTH-21st
An International Fetal and Newborn Growth Consortium dedicated to improving perinatal health through the development of new fetal and newborn growth standards, providing tools for the continuity of care from conception to 5 years of age.